Screener / SEC EDGAR /CIK 0001635088 /10-K filed May 20, 2026, compared with May 29, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Roivant Sciences Ltd. ROIV

Compare with peers Embed
SEC comment letters, last 20 years

1 review of ROIV's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Jun 15, 2021
Questions asked 35 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 35 numbered comments
  3. 3. Company replies 3 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-4

2021-06-15 to 2021-08-03 · 35 questions · 3 letters from the SEC, 3 from the company
No closing letter
AcquisitionsResults discussion (MD&A)Risk factorsIncome taxesRevenueLegal and contingencies
Market, Industry, and Other Data , page 1
SEC asked (1)
We note your statement regarding market data used in the prospectus in which you explain that your estimates are derived from your review and interpretation of certain sources and that investors are cautioned "not to give undue weight" to these estimates. Please revise this statement to eliminate any implication that investors are not entitled to rely on the information included in your registration statement.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 1 of the Amended Registration Statement accordingly.
Read in the reply
Summary of the Proxy Statement/Prospectus · Roivant Sciences Ltd., page 14
SEC asked (2)
Please disclose Riovant's history of net losses and lack of commercial revenue in this summary section.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 16 of the Amended Registration Statement accordingly.
Read in the reply
Summary of the Proxy Statement/Prospectus · Roivant Sciences Ltd., page 14
SEC asked (3)
Please clarify how you define "mid-to late-stage clinical development" and what factors you use to define your Phase 3 trials as "successful." Please quantify the number of drug candidates being tested in the nine International Phase 3 trials and the eight Phase 3 trials you deemed "successful." Additionally, clarify the current status of development for the the candidates for which you completed successful Phase 3
Rest of the question

trials.

ROIV answered
The Company respectfully acknowledges the Staff’s comment. The Company has removed all references to “mid-to late-stage clinical development” and further revised the disclosure on pages 16, 182, 233 and 313 of the Amended

Registration Statement accordingly.
Read in the reply
Interests of Certain MAAC Persons in the Business Combination , page 19
SEC asked (4)
Please quantify the aggregate dollar amounts contributed by the sponsor and affiliates and describe the nature of what the sponsor and the affiliates have at risk and are dependent on the completion of the business combination. Include the current value of the securities held, loans extended, fees due and out of pocket expenses for which the sponsor and affiliates are awaiting reimbursement.
Rest of the question

Provide similar disclosure for officers and directors, if material. Provide similar information in your risk factor section and "Interests of Certain MAAC Persons in the Business Combination" beginning on page 161.46 Milestone and Royalty payments that we are obligated to pay may be greater than anticipated.,

ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 21, 22, 190 and 191 of the Amended Registration

Statement accordingly.
Read in the reply
Interests of Certain MAAC Persons in the Business Combination , page 19
SEC asked (5)
Given that the milestone and royalty payments are provided for in your licensing agreements, it is not clear why they might be greater than you anticipate. Please revise to further explain this risk and why the amount of the payments and describe the types of payments that might unexpectedly come due prior to generating product sales.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 40 of the Amended Registration Statement accordingly.
Read in the reply
Risks Related to MAAC and the Business Combination, page 98
SEC asked (6)
Please highlight the risk that the sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable company or on term less favorable to shareholders rather than liquidate.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 116 of the Amended Registration
Read in the reply
Risks Related to MAAC and the Business Combination, page 98
SEC asked (7)
Please highlight the sponsors and public shareholders have different rates of return and clarify if the sponsors and affiliates can earn a positive rate of return on their investment, even if the other SPAC shareholders experience a negative rate of return in the post business combination company.
Rest of the question

Since MAAC sponsor and MAAC's officers and directors will not be eligible to be reimbursed for their out of pocket expenses..., page 101

ROIV answered
the Staff’s comment and has revised the disclosure on page 116 of the Amended Registration Statement accordingly.

Since MAAC sponsor and

MAAC’s officers and directors will not be eligible to be reimbursed for their out of pocket expenses..., page 101
Read in the reply
Risks Related to MAAC and the Business Combination, page 98
SEC asked (8)
Please quantify the out of pocket expenses incurred to date. Subsequent to the Consummation of the Business Combination, MAAC may be required to...,
ROIV answered
the Staff’s comment and has revised the disclosure on page 106 of the Amended Registration Statement accordingly.
Read in the reply
Risks Related to MAAC and the Business Combination, page 98
SEC asked (9)
Please highlight the risk presented by taking the company public through a merger rather than an underwritten offering by highlighting that an underwriter would be subject to liability for any material misstatements or omissions in a registration statement. Our warrant agreement designates the courts of the State of New York or the United States
ROIV answered
the Staff’s comment and has revised the disclosure on page 107 of the Amended Registration Statement accordingly.
Read in the reply
District Court for the Southern District. . . ., page 105
SEC asked (10)
Please revise this risk factor to disclose that there is also a risk that your exclusive forum provision may result in increased costs for investors to bring a claim.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 111 of the Amended Registration Statement accordingly.
Read in the reply
Background of the Business Combination, page 161
SEC asked (11)
Please identify the third party advisor and expand your disclosure to more specifically explain its role with respect to evaluations, analysis and due diligence.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the Background of the Business Combination section on pages 170 and 171 of the

Amended Registration Statement to identify the sponsor of Montes Archimedes Acquisition Corp. (“MAAC”), Patient Square Capital LLC (the “MAAC Sponsor”), and its role with respect to evaluations, analysis and due diligence of potential targets and has removed references to a third party advisor as the evaluations and due diligence were in fact prepared by the MAAC Sponsor.
Read in the reply
Background of the Business Combination, page 161
SEC asked (12)
Explain how you narrowed the potential targets from 70 to seven, describe each of the seven potential targets that entered into non-disclosure agreements with you and explain why and when each was eliminated as a potential target.
ROIV answered
the Staff’s comment and has revised the Background of the Business Combination section on pages 170 and 171 of the Amended Registration Statement accordingly to describe each of the seven potential business combination targets that were identified from an initial pool of 70, and how each was eliminated as a potential target.
Read in the reply
Background of the Business Combination, page 161
SEC asked (13)
Describe the analyses prepared by the third party advisor for each of the three remaining candidates.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the Background of the Business Combination section on pages 170 and 171 of the Amended Registration Statement accordingly to describe the analyses prepared by the MAAC Sponsor and when each was eliminated as a potential target.
Read in the reply
Background of the Business Combination, page 161
SEC asked (14)
Disclose the proposed terms Roivant provided MAAC on January 10, 2021 and explain how the terms changed during the course of your negotiations.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the Background of the Business Combination section on pages 173 through 180 of the Amended Registration Statement accordingly to describe the evolution of the terms of the business combination between MAAC and Roivant.
Read in the reply
Business of Roivant · Vants , page 203
SEC asked (15)
Please enlarge this figure, the development pipeline on page 203.1 and the graphic on page 207, as the text is too small to be legible. Additionally, indicate which of these Vants are publicly held.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 234 through 237, 240 and 250 through

253 of the Amended Registration Statement accordingly.
Read in the reply
Business of Roivant · Vants , page 203
SEC asked (16)
We note that some of the product candidates in your pipeline table on page 2.3.1 are being developed by vants that you do not control, such products being developed by Sio Gene Therapies and Arbutus. For each of these candidates describe your economic interests in the product candidate, such as receipt of potential milestone payments, royalty rights, commercialization rights.
Rest of the question

To the extent that your rights are limited to the potential appreciation in the value of your shares in the company, please remove them from this pipeline table and the individual vant pipeline tables beginning on page 241.1. Our Degrader Strategy, page 210

ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 1 of the Amended Registration Statement to clarify that certain summary statistics and other information presented in the proxy statement/prospectus, including its pipeline of drug candidates, include three entities in which the Company retains a substantial economic interest and has representation on the entities’ boards of directors: Arbutus Biopharma Corporation, Sio Gene Therapies Inc. and Datavant Holdings, Inc. (the “Non-Controlled Vants”).
Rest of the answer

On page 1 of the Amended Registration

Statement, the Company has further clarified that it does not have any further economic interests in the product candidates the Non-Controlled Vants are developing or their marketed technology products, as applicable, other than the potential appreciation in the value of the Company’s equity interest in these entities.

Read in the reply
Business of Roivant · Vants , page 203
SEC asked (17)
Please remove the reference to "potentially best-and first-in-class" as this statement implies an expectation of regulatory approval and is inappropriate given the stage of development for your programs. Ensure that similar disclosures concerning "best-inclass" and/or "first-in-class," which we note repeated numerous times in this section of the filing, are also removed.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has removed such disclosure on pages 243, 247, 254, 300, 305, 307, 310, 313 and 318 of the Amended Registration Statement accordingly.
Read in the reply
Platform Validation , page 212
SEC asked (18)
Please remove your statement on page 213 that you believe that Sumitomo’s decision to partner with Roivant serves to validate t the drug candidates that have been, and will be, generated by your technology. Efficacy determinations are the sole authority of the FDA and equivalent foreign regulators, implying that Sumitomo's decision validates the candidates is not appropriate.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has removed such disclosure on page 246 of the Amended Registration Statement accordingly.
Read in the reply
Arbutus Overview · Clinical data, page 283
SEC asked (19)
Please remove your disclosure that "AB-729 has been safe" in your Phase 1a/1b trial, as safety determinations are the exclusive purview of the FDA or other regulators.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has removed such disclosure on page 323 of the Amended Registration Statement
Read in the reply
Asset Acquisitions and License Arrangements, page 286
SEC asked (20)
Please disclose the expected expiry of the last-to-expire patent licensed under the Michigan Research Agreement and the Cross-License Agreement with Arbutus Biopharma Corporation;and revise the descriptions of your strategic agreement with Japan Tobacco to include a royalty range within ten percentage points for product sales of tapinarof.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 328, 329 and 331 of the Amended
Read in the reply
Legal Proceedings, page 320
SEC asked (21)
We note your disclosure on page 81 indicating that you have ongoing litigation related to patent disputes. These disclosures appear to conflict with your disclosure in this section that you are not presently a party to any material legal proceedings. Please revise your disclosure or tell us why you believe disclosure related to these legal proceedings is not required.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 361 and 362 of the Amended Registration Statement accordingly.
Read in the reply
Contractual Obligations and Commitments, page 338
SEC asked (22)
Please file the loan and security agreement between Dermavant and Hercules as an exhibit or tell us why you believe such filing is not required. Refer to Item 601(b)(10) of Regulation S-K.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and advises the Staff that Dermavant Sciences Ltd. has repaid all amounts outstanding under the loan and security agreement (the “Hercules Loan Agreement”) with Hercules Capital, Inc. in May 2021. Accordingly, the Company respectfully advises the Staff that it does not believe the Hercules Loan Agreement is required to be filed as an exhibit to the Amended Draft Registration Statement pursuant to Item 601(b)(10) of Regulation S-K.

In addition, the Company has revised the disclosure on pages 374, 376 and F-68 of the Amended
Rest of the answer

Registration Statement to disclose that the Hercules Loan Agreement has been fully repaid and terminated.

Financial Statements of Roivant Sciences Ltd for the Nine Months Ended December 31, 2020 and 2019 – Notes to Condensed Consolidated

Read in the reply
Notes to Condensed Consolidated Financial Statements · Note 9-Shareholders' Equity and Redeemable Non-Controlling Interest, page F-87
SEC asked (23)
You disclose on pages F-49 and F-50 that you consolidate Immunovant. Please clarify the percentage owned after Immunovant issued additional shares as discussed on page F-87 and if the additional share issuances by Immunovant in the nine months ended December 31, 2020 affected the accounting treatment in Roivant's financial statements.
ROIV answered
the Staff’s comment and advises the Staff that Roivant’s equity ownership interest in Immunovant was 57.5% as of both December 31, 2020 and March 31, 2021, in each case after taking into account all equity issuances that occurred through the relevant date. Accordingly, Roivant continued to consolidate Immunovant at each relevant date.
Read in the reply
Note 16-Subsequent Events · Acquisition of Silicon Therapeutics, page F-95
SEC asked (24)
We note that in March 2021 Roivant acquired Silicon Therapeutics, LLC for consideration of approximately $450.0 million, with additional cash payments payable subject to the satisfaction of certain regulatory and commercial milestones.
Rest of the question

Please tell us why the financial statements of Silicon Therapeutics are not significant to Roivant's financial statements such that the omission of those financial statements renders Roivant's financial statements substantially incomplete or misleading. In this regards, also please tell us your consideration of including the acquisition in the pro forma information on page 163. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

ROIV answered
The Company respectfully acknowledges the Staff’s comment and advises the Staff as follows. Based on the Company’s analysis of the significance tests set forth in rule in Rule 1-02(w) of Regulation S-X (“Rule 1-02(w)”), the

Company’s acquisition of the business of Silicon Therapeutics, LLC (“SiTX”) did not exceed the relevant 20% threshold on any of the three significance tests set forth in Rule 1-02(w), namely the asset test, the investment test or the income test.
Rest of the answer

For purposes for applying these tests, the Company used SiTX’s most recently completed pre-acquisition fiscal year end (December 31,

2020) and the Company’s most recently completed pre-acquisition fiscal year end (March 31, 2020). The significance tests calculations were as follows:

•

Asset test: As of December 31, 2020, SiTX had total assets of approximately $20 million. As of

March 31, 2020, the Company had total assets of approximately $2.5 billion. The Company’s interest in SiTX’s total assets represents less than 1% of the Company’s total assets as of March 31, 2020.

Investment test: As the Company’s common shares are not publicly traded, the Company evaluated the purchase price, including the fair value of the contingent consideration, as compared to consolidated total assets, as required by Rule 1-02(w). The purchase price, approximately $455 million, was determined by adding the up-front consideration of approximately $450 million and the fair value of contingent consideration of approximately $5 million, resulting in a significance under the investment test of approximately 18% of the Company’s total assets of approximately $2.5 billion as of March 31, 2020.

Income test: SiTX had no revenue recorded for the years ending December 31, 2020 and December 31, 2019.

Neither SiTX nor Roivant had material revenue in either of the two most recently completed fiscal years and, as such, only the test based on income from continuing operations before taxes was performed. For the fiscal year ended December 31,

2020, SiTX’s pre-tax loss was approximately $28 million. For the fiscal year ended March 31, 2020, Roivant’s loss from continuing operations before income taxes was approximately

$512 million. Roivant’s share of SiTX’s loss, calculated as $28 million divided by $512 million, therefore equals approximately 5% of Roivant’s loss from continuing operations before income taxes in the relevant period.

Based on the above assessment, the acquisition of SiTX is not considered significant for purposes of Rule 1-02(w) and therefore Roivant did not provide separate financial statements of SiTX or include pro forma financial information for SiTX as part of the December 31, 2020 pro forma financial information included in the proxy statement/prospectus. The Company advises the Staff that because the acquisition closed in March 2021, the acquisition of SiTX is reflected in the Company’s audited financial statements for the fiscal year ended

March 31, 2021 included in the proxy statement/prospectus.

Read in the reply
Material United States Tax Considerations, page 135
SEC asked (1)
Please delete the disclaimers on page 136 and 148 that material U.S. tax considerations are provided for information purposes only.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 136 and 148 of the Amended Registration Statement accordingly.
Read in the reply
Material United States Tax Considerations, page 135
SEC asked (2)
We note that Roivant believes it will not be treated as a U.S. corporation for U.S. federal income tax purposes and the absence of guidance as to whether the transaction qualifies as as a reorganization for tax purposes.
Rest of the question

Please provide a tax opinion noting the uncertainty with respect to whether Roivant will be treated as a US corporation and the inability to opine as to whether the transaction will qualify as a reorganization for tax purposes. Please identify counsel in your disclosure. Refer to Item 601(b)(8) of Regulation S-K and, for guidance, Section II.B.1.c. and Section III.A. of Staff Legal Bulletin No. 19.

ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 135, 137, 139 and 140 of the Amended Registration Statement to provide that, subject to the assumptions, qualifications and limitations set forth in the disclosure and in the opinions filed as Exhibits 8.2 and 8.3 to the Amended Registration Statement, (i) the statements of law and legal conclusions set forth under the headings “MATERIAL UNITED STATES TAX CONSIDERATIONS—Tax Consequences of Exercising Redemption

Rights,” “—Tax Consequences of the Merger” and “—Additional Requirements for Tax
Rest of the answer

Deferral,” constitute the opinion of Kirkland & Ellis LLP and (ii) the statements of law and legal conclusions set forth in the remainder of the discussion under the heading “MATERIAL UNITED STATES TAX CONSIDERATIONS” constitute the opinion of Davis Polk & Wardwell LLP. As discussed above, we have attached opinions as Exhibits 8.2 and 8.3 to the Amended Registration Statement.

Read in the reply
Material United Kingdom Tax Considerations, page 149
SEC asked (3)
Please remove the disclaimers indicating that the discussion of material tax considerations are provided for informational purposes only.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 149 of the Amended Registration Statement accordingly.
Read in the reply
Material United Kingdom Tax Considerations, page 149
SEC asked (4)
We note that you have filed a short for tax opinion as exhibit 8.1. However the prospectus disclosure fails to identify tax counsel or clearly set forth counsel's opinion or the basis for such opinion. Please revise to eliminate the qualification of discussion as a "general summary" and set forth counsel's opinion and its bass for each material tax consequence.
Rest of the question

If counsel is unable to opine, clearly state its inability, provide a reason for the inability and discuss the possible alternatives and risks to investors of each tax consequence. Refer to Item 601(b)(8) of Regulation S-K and, for guidance, Section II.B.1.c. and Section III.A. of Staff Legal Bulletin No. 19.

ROIV answered
the Staff’s comment and has revised the disclosure on page 149 of the Amended Registration Statement accordingly.
Read in the reply
Background of the Business Combination, page 169
SEC asked (5)
We note your response to comment 11 in which you state that you have removed references to a third party advisor; however, we note that page 170 states that the MAAC Sponsor managed the "coordination of third party advisors." Please advise and, if necessary, identify these third party advisors and their role with respect to evaluations, analysis and due diligence.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 170 of the Amended Registration Statement accordingly.

MAAC notes that, other than as indicated in the revised Background of the Business Combination disclosure, none of MAAC’s third party advisors were involved in transaction negotiations or valuation discussions.
Read in the reply
Summary of MAAC Financial Analysis, page 184
SEC asked (6)
Please further explain how the presented comparable company and selected Precedent Transaction Analyses analyses support your determination that the equity value of Roivant is greater than the $7.3 billion pro forma equity value ultimately agreed upon. Development Pipeline, page 237
ROIV answered
the Staff’s comment and has revised the disclosures on pages 185 through 189 of the Amended Registration Statement accordingly.
Read in the reply
Summary of MAAC Financial Analysis, page 184
SEC asked (7)
We note your response to comment 16 and reissue the comment. Given that Riovant no longer holds a controlling interest in these companies and has a financial interest limited to the appreciation of your investment in these companies, it is not appropriate to include them in the list of product candidates in the pipeline. Please remove them from the table. Platform Validation, page 246
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 237 and 252 of the Amended Registration Statement
Read in the reply
Summary of MAAC Financial Analysis, page 184
SEC asked (8)
We note your response to comment 18 please revise the title of this subsection and remove the statement that you believe Sumitomo's decision serves to validate the quality of your platform. The title and statement are speculative and imply that Sumitomo's decision is predictive of FDA efficacy determinations.
ROIV answered
the Staff’s comment and has revised the disclosure on pages 16, 233, 237 and 246 of the Amended Registration Statement accordingly.
Read in the reply
Material United States Tax Considerations, page 135
SEC asked (1)
We note your response to comment 2 and your amended disclosure on page 139 that "neither MAAC nor Roivant has received or sought, an opinion of counsel that the Merger qualifies as a reorganization, and neither MAAC nor Roivant intends to request a ruling from the IRS regarding the U.S.
Rest of the question

federal income tax treatment of the Merger." Please make clear in the tax opinion itself that counsel is unable to opine on whether the transaction qualifies as as a reorganization for tax purposes and that counsel is unable to opine on whether the company will be treated as a U.S. corporation for U.S. federal income tax purposes. While we note that the Kirkland & Ellis tax opinion attached as Exhibit 8.3 states that it expresses "no opinion" on these tax issues, it is not clear why it is unable to do this. Please provide an explanation for this inability in the tax opinion itself and discuss the possible alternatives and risks to investors of each tax consequence. Refer to Item 601(b)(8) of Regulation S-K and, for guidance, Section II.B.1.c. and Section III.A. of Staff Legal Bulletin No. 19.

ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the Kirkland & Ellis tax opinion and disclosure on page 139 of the

Amended Registration Statement to address the Staff’s comment with respect to qualification of the merger as a reorganization. However, the inquiry as to whether the application of Section 7874 will cause the Company to be treated as a

U.S. corporation for U.S.
Rest of the answer

federal income tax purposes is highly fact-intensive, and whether the ownership test has been satisfied can only be finally determined after completion of the Business Combination, by which time there may have occurred adverse changes to the relevant facts and circumstances. Nevertheless, the Company has performed an analysis as to the Section 7874 consequences of the Business Combination, based on which the Company expects that it will not be treated as a U.S. corporation. The disclosure in the section titled “Treatment of Roivant as a Non-U.S. Corporation for U.S. Federal Income Tax Purposes” is drafted in a manner consistent with recent precedent transactions of a similar nature.

Read in the reply
Material United Kingdom Tax Considerations, page 149
SEC asked (2)
We note your response to comment 4. It appears, however, that the filing still does not set forth counsel's opinion or the basis for such opinion. If counsel is unable to opine, the tax opinion should be revised to clearly state its inability, provide a reason for the inability
ROIV answered
The Company respectfully acknowledges the Staff’s comment and respectfully turns the staff’s attention to the current disclosure on page 149 of the Amended Registration Statement, which addresses the Staff’s comment, as discussed with the Staff on July 30th.
Read in the reply
Summary of MAAC Financial Analysis, page 184
SEC asked (3)
We note your response to comment 6; however, it is still not clear how how you arrived at the $7.3 billion pro forma equity value, especially considering the various valuations detailed on pages 187 to 189. Please revise your disclosure to more specifically explain how you calculated this $7.3 billion valuation.
ROIV answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosures on pages 185 through 188 of the Amended Registration Statement accordingly.
Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
11 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 17 letters filed since 2021-06-16. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.